Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 326 - 350 of 11588 in total
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Categories: … MATE 1 Substrates with a Narrow Therapeutic Index ... MATE 2 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index …
Chloroprocaine is an ester local anesthetic commonly available in its salt form, chloroprocaine hydrochloride. Similar to other local anesthetics, it increases the threshold for electrical excitation in nerves by slowing the propagation of the nerve impulse and reducing the rate of rise of the action potential. The pharmacological profile of...
Approved
Investigational
Matched Description: … [L43402] The pharmacological profile of chloroprocaine is characterized by a short latency and duration ... Chloroprocaine can be given as an injection, and is available in formulations with and without methylparaben as a
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions.[L7616,L7619,A181589,A181583,A181697] The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the...
Approved
Matched Description: … Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages …
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Description: … Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant ... Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion ... form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Trichloroethylene is a halocarbon commonly used as an industrial solvent, not to be confused with the similar 1,1,1-trichloroethane, also known as chlorothene. It has been sold under a variety of trade names including Trimar and Trilene and used as a volatile anesthetic and as an inhaled obstetrical analgesic. Environmental exposure,...
Approved
Matched Description: … It has been sold under a variety of trade names including Trimar and Trilene and used as a volatile anesthetic ... Trichloroethylene is a halocarbon commonly used as an industrial solvent, not to be confused with the ... Environmental exposure, particularly groundwater and drinking water contamination from industrial discharge, is a
Matched Categories: … Compounds used in a research, industrial, or household setting …
Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase (GAA) enzyme. GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. In Pompe disease, the...
Approved
Investigational
Matched Description: … Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe ... disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase ( ... [A232955] Avalglucosidase alfa is a recombinant form of GAA that restores deficient enzyme levels. …
Aspergillus fumigatus is a fungus which can provoke allergic reactions. Aspergillus fumigatus extract is used in allergenic testing.
Approved
Matched Description: … Aspergillus fumigatus is a fungus which can provoke allergic reactions. …
Matched Mixtures name: … A Mold Mixture ... A Mold Mixture ... A Mold Mixture …
Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies. Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, is a focal treatment for localized prostate cancer. It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland. Padeliporfin...
Approved
Experimental
Matched Description: … [A244559] Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, is a ... Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted …
Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by...
Approved
Investigational
Matched Description: … A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) ... links between nucleotides are replaced with a phosphorodiamidate linkage. ... Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of …
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Approved
Matched Description: … Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase ... Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (> …
Infection with pathogenic filoviruses, such as Zaire ebolavirus (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as 90%.[A225933, A225938] Virtually all steps of the EBOV lifecycle have been targeted for therapeutic development. However, to date, the most successful...
Approved
Investigational
Matched Description: … [A225933] Ansuvimab, formerly mAb114, is a fully human IgG1 mAb derived from a survivor of the 1995 Kikwit ... GP1,2 surface glycoprotein, as evidenced by the previously approved INMAZEB™ (REGN-EB3, a ... [A225943, A225948, A226035] A randomized, controlled trial of four investigational therapies for Ebola …
A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan...
Approved
Investigational
Matched Description: … It was formerly used as a war gas. ... A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers....
Approved
Investigational
Matched Description: … [L10986] It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic ... [A189528] A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset ... of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of …
Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
Approved
Investigational
Withdrawn
Matched Categories: … Compounds used in a research, industrial, or household setting …
Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties.[A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress. In patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 pathway is impaired, and Nrf2 activity...
Approved
Investigational
Matched Description: … Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory ... ,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a ... In patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 …
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Description: … All three mAbs bind to a distinct portion of the GP1,2 glycoprotein and collectively provide ... [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions ... neutralizing and cytotoxic (i.e. through Fc-mediated immune effector function) antibody effects to play a
Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis.
Approved
Matched Description: … Dyphylline is a theophylline derivative with broncho- and vasodilator properties. …
Matched Mixtures name: … ESPEKTAN A ŞURUP, 100 ML …
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive...
Approved
Matched Description: … First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class ... Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by ... Compared to [glipizide], another second SU drug, glimepiride has a longer duration of action. …
A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.
Approved
Vet approved
Matched Description: … A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. …
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Description: … Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions ... [L10598] It is also available in a combination product with [formoterol].[L10619] …
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Description: … Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the...
Approved
Investigational
Matched Description: … Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic …
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine.[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer...
Approved
Matched Description: … Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar …
Matched Products: … ANHITEN-A
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation...
Approved
Investigational
Matched Description: … Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular …
Matched Categories: … UGT1A1 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Displaying drugs 326 - 350 of 11588 in total